- Previous Close
5.7300 - Open
5.4650 - Bid 4.1700 x 200
- Ask 6.2500 x 200
- Day's Range
4.7700 - 5.9000 - 52 Week Range
4.2100 - 11.2000 - Volume
106,260 - Avg. Volume
57,430 - Market Cap (intraday)
29.055M - Beta (5Y Monthly) -2.20
- PE Ratio (TTM)
-- - EPS (TTM)
-11.6700 - Earnings Date May 12, 2025 - May 16, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
15.00
KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
www.kalarx.comRecent News: KALA
View MorePerformance Overview: KALA
Trailing total returns as of 4/2/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KALA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KALA
View MoreValuation Measures
Market Cap
34.90M
Enterprise Value
22.74M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
5.09
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-43.75%
Return on Equity (ttm)
-430.96%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-38.96M
Diluted EPS (ttm)
-11.6700
Balance Sheet and Cash Flow
Total Cash (mrq)
49.2M
Total Debt/Equity (mrq)
540.01%
Levered Free Cash Flow (ttm)
-23.51M